6533b7d9fe1ef96bd126d688

RESEARCH PRODUCT

Interferon-alpha combined with cytarabine in chronic myelogenous leukemia - clinical benefits.

Th. FischerM. Lindauer

subject

OncologyCancer Researchmedicine.medical_specialtyCombination therapyAlpha interferonInterferonhemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChronic phase CMLClinical Trials as Topicbusiness.industryCytarabineInterferon-alphaHematologymedicine.diseaseSurvival benefitOncologyToxicityCytarabinebusinessChronic myelogenous leukemiamedicine.drug

description

During the last decade, several studies have evaluated the treatment of chronic phase chronic myeloid leukemia (CML) with a combination of interferon (IFN)-alpha and low- dose cytarabine (Ara-C). This combination therapy has been shown to be superior compared to monotherapy with IFN-alpha in randomized studies with regard to hematologic and cytogenetic remissions. However, the survival benefit is small, and the toxicity of the combination therapy is high. This paper reviews the published studies on IFN-alpha/low-dose Ara-C for the treatment of chronic phase CML and discusses the value of the combination therapy.

yearjournalcountryeditionlanguage
2001-05-30Leukemialymphoma
10.3109/10428190109060343https://pubmed.ncbi.nlm.nih.gov/11378570